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Abstract
Background: We report phase 1b data from patients enrolled in the JAVELIN Solid Tumor clinical trial
(NCT01772004) with unresectable stage IIIC or IV melanoma that had progressed after ≥1 line of therapy for
metastatic disease.
Patients and methods: Patients received avelumab (10 mg/kg)—a human anti–PD-L1 antibody. Assessments
included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.
Results: As of December 31, 2016, 51 patients were treated and followed for a median of 24.2months (range, 16.1–31.5).
Most patients had cutaneous (n = 28 [54.9%]) or ocular (n = 16 [31.4%]) melanoma and had received a median of 2 prior
lines of therapy (range, 0–4), including ipilimumab (n = 26 [51.0%]). The confirmed ORR was 21.6% (95% CI, 11.3–35.3;
complete response, 7.8%; partial response, 13.7%). The median duration of response was not estimable (95%
CI, 2.6 months-not estimable). Median PFS and OS were 3.1 months (95% CI, 1.4–6.3) and 17.2 months (95% CI,
6.6-not estimable), respectively. Subgroup analyses suggested meaningful clinical activity (ORR [95% CI]) in
patients with non-ocular melanoma (31.4% [16.9–49.3]), PD-L1–positive tumors (42.1% [20.3–66.5]), or prior
ipilimumab therapy (30.8% [14.3–51.8]). Thirty-nine patients (76.5%) had a treatment-related adverse event
(TRAE), most commonly infusion-related reaction (29.4%), fatigue (17.6%), and chills (11.8%); 4 patients (7.8%)
had a grade 3 TRAE. Five patients (9.8%) had an immune-related TRAE (all were grade 1/2). No grade 4 TRAEs
or treatment-related deaths were reported.
Conclusion: Avelumab showed durable responses, promising survival outcomes, and an acceptable safety
profile in patients with previously treated metastatic melanoma.
Trial registration: ClinicalTrials.gov identifier: NCT01772004.
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Introduction
Cutaneous melanoma (the most common melanoma
subtype) is the 15th most prevalent cancer worldwide,
with an estimated 232,000 diagnoses each year, and
accounts for 1.6% of all cancers [1]. Non-cutaneous
melanoma comprises less common, difficult-to-treat
melanoma subtypes that occur on mucosal membranes
of the head and neck and membranes lining the gastro-
intestinal and genitourinary tracts [2]. A very rare
melanoma subtype arises at the uvea of the eye (also
referred to as ocular melanoma). Most patients with
cutaneous melanoma initially present with localized dis-
ease (84%), 9% with regional disease, and 4% with distant
metastatic disease [3]. Patients with distant metastatic
cutaneous melanoma have historically had poor progno-
ses (estimated 5-year survival rate of 17%), compared
with 98% and 63% for patients with localized and re-
gional disease, respectively, as shown in comprehensive
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analyses of US patient data collected between 2005 and
2011 [3]. However, long-term survival rates for patients
with metastatic disease are improving with the incorpor-
ation of novel treatment options [4, 5], such as BRAF-
and MEK-targeted therapies, intratumoral oncolytic her-
pes viral therapies, and immune checkpoint inhibitors
(ICIs) targeting cytotoxic T-lymphocyte associated–pro-
tein 4 (CTLA-4) and programmed cell death-1 (PD-1)
[6]. Notably, cutaneous melanoma is typically character-
ized by extensive tumor infiltration by T cells, high
mutational burden, and an immunosuppressive pheno-
type, thereby supporting a role for ICIs. In contrast, the
rarer, non-cutaneous subtypes are distinct from cutane-
ous melanoma with respect to presentation, staging, re-
sponse to treatment, and patterns of progression [7–9].
Indeed, pembrolizumab, nivolumab, ipilimumab, and the
combination of nivolumab and ipilimumab have demon-
strated efficacy and are now approved by the United States
Food and Drug Administration (FDA) and European
Commission as treatment options for patients with
advanced cutaneous melanoma [10–12].
Avelumab is a human anti–programmed death-ligand
1 (PD-L1) IgG1 monoclonal antibody that inhibits the
PD-L1/PD-1 immune checkpoint [13]. Unlike other
anti–PD-L1/PD-1 antibodies, avelumab contains a native
Fc region and is capable of engaging natural killer cells
to induce innate effector function against tumor cells, as
shown in preclinical models [14, 15]; additional investi-
gation is needed to determine the contribution of innate
effector function to the overall antitumor response of
avelumab. Avelumab is the first FDA- and European
Commission—approved treatment option for patients
with metastatic Merkel cell carcinoma—a rare and
aggressive cutaneous malignancy that is the second most
common cause of skin-cancer death after melanoma [16,
17]. Avelumab is also FDA-approved for the treatment
of patients with locally advanced or metastatic urothelial
carcinoma whose disease progressed during or following
platinum-containing chemotherapy.
The safety and efficacy of avelumab has been investi-
gated in the large, multicohort, phase 1 JAVELIN Solid
Tumor clinical trial. In the phase 1a, dose-escalation
part of the study, avelumab was safely administered at
doses up to 20mg/kg every 2 weeks (Q2W). Based on
pharmacokinetic and pharmacodynamic data, avelumab
10mg/kg Q2W was chosen for further investigation
[13]. Avelumab has shown acceptable safety and durable
antitumor activity in multiple tumor types investigated
in the phase 1b, dose-expansion part of the study, in-
cluding non-small cell lung cancer, urothelial carcinoma,
and metastatic breast cancer [18–21]. Here, we report
the safety and efficacy from a cohort of previously
treated patients with locally advanced or metastatic
melanoma enrolled in the phase 1b, dose-expansion part
of the JAVELIN Solid Tumor trial with ≥16 months of
follow-up.
Materials and methods
Study design and patients
JAVELIN Solid Tumor is an ongoing, international,
multicenter, multicohort, open-label, dose-escalation and
dose-expansion, phase 1 trial of avelumab in patients
with advanced solid tumors (NCT01772004). In this
phase 1b, dose-expansion cohort, eligible patients had
histologically or cytologically confirmed stage IIIC or IV
unresectable melanoma (according to the American
Joint Committee on Cancer/Union for International
Cancer Control [AJCC/UICC] TNM staging system, 7th
edition) [22, 23] and were required to have progressive
disease after ≥1 prior standard therapy for metastatic
disease. Other eligibility criteria included an Eastern Co-
operative Oncology Group performance status (ECOG
PS) of 0 or 1; age≥18 years; adequate hematologic, hep-
atic, and renal function; no evidence of brain metastases;
and an available fresh or archival tumor specimen.
Patients were not selected based on tumor PD-L1 ex-
pression. Patients with ocular melanoma were permitted
to be enrolled. Patients who received prior therapy with
anti–PD-L1/PD-1 antibodies were excluded; however,
patients who received prior therapy with anti–CTLA-4
antibodies were eligible. Other exclusion criteria
included any previous anticancer treatment or major
surgery ≤28 days before the start of study treatment;
other cancer diagnosis ≤5 years prior to study entry;
rapidly progressive disease; previous stem cell or solid
organ transplant; known hypersensitivity to monoclonal
antibodies; active or history of autoimmune disease or
immunodeficiency; significant acute or chronic infection
(e.g., human immunodeficiency virus, hepatitis B virus,
hepatitis C virus); persisting toxicity related to prior ther-
apy of grade >1 (except for grade 2 sensory neuropathy);
and being pregnant or lactating. Any use of steroids was
tapered before study treatment, except for patients with
adrenal insufficiency—who could continue treatment at a
physiological replacement dose.
This trial was conducted in accordance with the ethics
principles of the Declaration of Helsinki and the Inter-
national Council on Harmonization Guidelines on Good
Clinical Practice. The protocol was approved in each
center by the institutional review board or independent
ethics committee. All patients provided written consent
before their enrollment.
Treatments and assessments
Avelumab 10 mg/kg was administered as a 1-h intraven-
ous infusion Q2W until progression, unacceptable
toxicity, or occurrence of any other protocol-specified
criterion for withdrawal. Dose modifications were not
Keilholz et al. Journal for ImmunoTherapy of Cancer            (2019) 7:12 Page 2 of 13
permitted. The following adverse events (AEs) required
treatment discontinuation: any grade 4 AE, except single
laboratory values out of the normal range that were
unrelated to study treatment, without clinical correlate,
and resolved in ≤7 days with medical management; any
grade ≥3 treatment-related amylase or lipase abnormality
that was not associated with symptoms or clinical mani-
festations of pancreatitis and did not require dose delay;
increased ECOG PS ≥3 that did not resolve to ≤2 by
cycle day 14 of the following cycle (infusions were not
given during the following cycle if the ECOG PS was ≥3
on the day of administration); or any grade 3 AE except
for transient (≤6 h) influenza-like symptoms or fever
controlled with medical management; fatigue, local
infusion-related reaction (IRR), headache, nausea, or em-
esis that resolved to grade ≤ 1 in ≤24 h; single laboratory
values out of the normal range that were unrelated to
study treatment and without clinical correlate (excluding
grade ≥3 increase in liver enzyme concentrations) that
resolved to grade ≤1 in ≤7 days; and tumor flare (local
pain, irritation, or localized rash at sites of known or
suspected malignant tissue). Grade 2 AEs were managed
via reductions in infusion rates and dose delays. AEs that
did not resolve to grade ≤1 by the end of the next
treatment cycle or that recurred, resulted in permanent
withdrawal of avelumab (except for hormone insufficien-
cies that could be managed by replacement therapy).
Premedication with an antihistamine and acetaminophen
was administered 30 to 60 min prior to all infusions
of avelumab.
Biweekly safety assessments included documentation
of AEs and concurrent medications, and ECOG PS;
other safety assessments were conducted every 6 weeks
and included physical examinations and clinical labora-
tory tests (hematology and serum chemistry). AEs and
laboratory abnormalities were classified and graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events (NCI-CTCAE)
version 4.0. A serious AE was defined as a life-threaten-
ing event that required hospitalization, resulted in dis-
ability, was a congenital anomaly, or resulted in death.
IRRs (IRR, drug hypersensitivity, or hypersensitivity) oc-
curring on the day of or the day after infusion and IRR
symptoms occurring ≤1 day after infusion that resolved
≤2 days after onset were included. Immune-related AEs
(irAEs) were identified using a prespecified list of AE
terms and concomitant medication (eg, corticosteroids
and hormone replacement) and relationship to study
treatment was based on investigator assessment.
Clinical activity was assessed every 6 weeks by the
investigators according to Response Evaluation Criteria
in Solid Tumors (RECIST) version 1.1 [24]. Radiographic
tumor assessments were performed at baseline and then
every 6 weeks thereafter for the first 12 months, then
every 12 weeks. For patients who had a partial response
or complete response, a confirmatory computed tomog-
raphy or magnetic resonance imaging scan was
performed no sooner than 28 days later and preferably at
the scheduled 6-week interval visit.
PD-L1 expression was assessed using a proprietary
immunohistochemistry assay (Dako PD-L1 immunohis-
tochemistry 73-10 pharmDx; Dako, Carpinteria, CA)
[18–21]. In this study, PD-L1–positive status was
defined prospectively using a cutoff of ≥1% of tumor cell
membrane staining of any intensity; other PD-L1 cutoffs
were also evaluated.
Outcomes
The primary objectives of the JAVELIN Solid Tumor
trial were to assess dose-limiting toxicities within the
first 3 weeks of treatment in the dose-escalation part of
the study and confirmed best overall response as adjudi-
cated by an independent review committee in specified
expansion cohorts (not including melanoma) [13]. Pre-
specified endpoints in the melanoma cohort included
investigator-assessed confirmed best overall response per
RECIST v1.1, progression-free survival (PFS) per
RECIST v1.1, overall survival (OS), tumor PD-L1 expres-
sion, and safety. All subgroup analyses of patients with
ocular/non-ocular melanoma and those who received
prior ipilimumab therapy were exploratory. Changes in
the sum of target lesion diameters from baseline were
evaluated in patients with baseline tumor assessments
and ≥1 postbaseline assessment.
Statistical analysis
A sample size of 50 patients was planned to provide
point estimates and 95% Clopper-Pearson CIs for an ob-
jective response rate (ORR) of 10% (95% CI, 3.3–21.8%)
in the case of 5 responders, and of 20% (95% CI, 10.0–
33.7%) in the case of 10 responders. Time-to-event end-
points were estimated with the Kaplan-Meier method,
and CIs for the medians were calculated using the
Brookmeyer-Crowley method. P values for association
between categorical variables were determined using the
Fisher exact test. Safety and clinical activity were ana-
lyzed in all patients who received ≥1 dose of avelumab.
Results
Baseline patient characteristics
As of December 31, 2016, 51 patients had received
avelumab monotherapy (Table 1). Most patients had
cutaneous melanoma (n = 28 [54.9%]), and 16 patients
(31.4%) had ocular melanoma. Among all patients, 17
(33.3%) and 9 (17.7%) received 2 or ≥3 prior lines of
therapy for metastatic or locally advanced disease,
respectively; patients had received a median of 2 prior
treatments (range, 0–4 treatments). Most patients
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(n = 26 [51.0%]) had received prior therapy with ipili-
mumab (anti–CTLA-4).
At the time of data cutoff, the median duration of
treatment with avelumab was 3.2 months (range, 0.5–
27.2 months), and the median follow-up time was 24.2
months (range, 16.1–31.5 months). Patients had received
a median of 7 doses of avelumab (range, 1–56 doses).
At the time of analysis, treatment was ongoing in 6
patients (11.8%). Reasons for treatment discontinu-
ation included progressive disease (n = 30 [58.8%]),
AE (n = 8 [15.7%]), consent withdrawal (n = 3 [5.9%]),
and death (n = 2 [3.9%]).
Antitumor activity
Of all 51 patients, the confirmed ORR per RECIST v1.1
was 21.6% (95% CI, 11.3–35.3) (Table 2), with complete
response in 4 patients (7.8%), partial response in 7
patients (13.7%), stable disease in 16 patients (31.4%),
and progressive disease in 18 patients (35.3%); disease
control was achieved in 52.9% of patients. Six patients
(11.8%) were not evaluable for best overall response due
to lack of available postbaseline assessments (n = 4),
postbaseline assessments with an overall response that
was non-evaluable (n = 1), or stable disease of insuffi-
cient duration (n = 1). Most responses occurred rapidly:
of the 11 responses, 4 occurred by first postbaseline as-
sessment (1 complete response and 3 partial responses),
and 4 additional patients achieved a partial response by
the second postbaseline assessment (Fig. 1a). Responses
were ongoing in 8 of 11 responding patients (72.7%) at
the cutoff date. The median duration of response (DOR)
was not estimable (range, 2.6 months-not estimable).
Based on Kaplan-Meier estimates, 80.0% (95% CI, 40.9–
94.6) and 68.6% (95% CI, 30.5–88.7) of responding pa-
tients had DOR of 6 and 12 months, respectively. Of 45
patients with baseline and postbaseline assessments, 15
(33.3%) experienced tumor shrinkage of ≥30% (Fig. 1b).
Median PFS was 3.1months (95% CI, 1.4–6.3) (Table 2),
and 14 patients (27.5%) were event-free at the cutoff date.
The 6- and 12-month rates of PFS were 39.2 and 17.4%,
Table 1 Patient demographics and baseline characteristics
Characteristic N = 51
Age, n (%)
<65 years 28 (54.9)
≥65 years 23 (45.1)







American Indian or Alaskan 1 (2.0)
Black or African American 1 (2.0)
Other 12 (23.5)
ECOG performance status, n (%)
0 25 (49.0)
1 26 (51.0)





Time from initial diagnosis to study entry, years
Median 4.3
Range 0.3–33.5
Time since first metastatic disease, months
Median 14.8
Range 2.3–168.9
PD-L1 expression (≥1% of tumor cells), n (%)
Positive 19 (37.3)
Negative 20 (39.2)
Not evaluable 12 (23.5)







Median (range) 2 (0–4)





Table 1 Patient demographics and baseline characteristics
(Continued)





Investigational drug 4 (7.8)
Paclitaxel 3 (5.9)
Sorafenib 3 (5.9)
a Includes melanoma of the canthus (n = 1) and unknown primary (n = 4)
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respectively. The PFS curve demonstrated a stable plateau
following the 12-month time point (Fig. 2a).
Median OS was 17.2 months (95% CI, 6.6-not estim-
able) (Table 2 and Fig. 2b), and 27 patients (52.9%) were
alive at the cutoff date. The 12- and 24-month rates of
OS were 59.4% and 43.7%, respectively.
Subgroup analyses
Of 35 patients with cutaneous or mucosal melanoma,
melanoma of the canthus, or unknown primary (collect-
ively referred to as patients with non-ocular melanoma),
the ORR was 31.4% (95% CI, 16.9–49.3) (Table 2), which
included the previously described 11 patients with an
objective response. ORRs according to tumor site
subgroups are shown in Additional file 1: Table S1.
In patients with non-ocular melanoma, median PFS
was 3.9 months (95% CI, 2.0–9.0), and 6- and 12-month
PFS rates were 47.1 and 25.9%, respectively. Median OS
was 17.2 months (95% CI, 9.3-not estimable), and 12-
and 24-month OS rates were 64.9% and 44.8%, respect-
ively. No objective responses were observed in the 16 pa-
tients with ocular melanoma, although 7 of 16 patients
(43.8%) had transient stable disease. Median PFS was 1.7
months (95% CI, 1.4–4.1), with 6- and 12-month rates of
PFS of 23.4 and 0%, respectively. Median OS was not yet
reached (95% CI, 3.6 months-not estimable); the
12-month OS rate was 50.0% and the 24-month OS rate
was not estimable (Table 2, Fig. 3, and Additional file 2:
Figure S1).
Of 39 patients with biopsy material assessable for
PD-L1 expression, those with PD-L1–positive tumors at
a 1% cutoff (n = 19) had a confirmed ORR of 42.1% (95%
CI, 20.3–66.5): 2 patients experienced a complete re-
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Fig. 1 Time to and duration of response (a) and change in tumors in all patients (b)
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CI, 0–16.8) in patients with PD-L1–negative tumors
(n = 20) (Fisher exact test, P = 0.001); in patients whose
tumors were not evaluable for PD-L1 expression (n = 12),
the ORR was 25.0% (95% CI, 5.5–57.2): 2 patients expe-
rienced a complete response and 1 a partial response
(Table 2 and Additional file 2: Figure S1). If confined to
patients with non-ocular melanoma, objective re-
sponses were observed in 8 of 14 patients (57.1% [95%
CI, 28.9–82.3]) with PD-L1–positive tumors vs an ORR
of 0% (95% CI, 0–26.5) in patients with PD-L1–negative
tumors (n = 12) (Fisher exact test, P = 0.002); of 9 pa-
tients whose tumors were not evaluable for PD-L1 ex-
pression, 3 objective responses were observed (33.3%
[95% CI, 7.5–70.1]) (Additional file 3: Table S2).
Of 45 patients with baseline and postbaseline measure-
ments, 23 patients had a reduction in the sum of target
lesion diameters of any kind: 12 patients with PD-L1–
positive tumors, 5 with PD-L1–negative tumors, and 6
patients whose tumors were not evaluable for PD-L1
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Fig. 2 PFS (a) and OS (b) in all patients
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was ≥30% in 10 patients with PD-L1–positive tumors, in
1 patient with a PD-L1–negative tumor, and in 4
patients with tumors not evaluable for PD-L1 expres-
sion. The changes in the sums of target lesions between
baseline and best postbaseline assessment according to
tumor site are shown in Additional file 4: Figure S2.
Median PFS was 6.3 months (95% CI, 2.1–11.1; HR,
0.41 [95% CI, 0.20–0.86]) in patients with PD-L1–posi-
tive tumors, 1.4 months (95% CI, 1.3–4.1) in those
with PD-L1–negative tumors, and 3.3 months (95%
CI, 1.4-not estimable; HR, 0.39 [95% CI, 0.16–0.97])
in those with tumors not evaluable for PD-L1 expression
(Table 2 and Fig. 4b). Patients with PD-L1–positive
tumors had a median OS of 24.9months (95% CI, 6.2-not
estimable; HR, 0.34 [95% CI, 0.13–0.87]) compared with
5.3 months (95% CI, 3.8–16.2) in those with PD-L1–nega-
tive tumors; median OS was not estimable (95% CI,
2.1-not estimable; HR, 0.21 [95% CI, 0.05–0.79]) in
patients whose tumors were not evaluable for PD-L1 ex-
pression (Table 2 and Fig. 4c). If confined to patients with
non-ocular melanoma, median PFS was 7.9months (95%
CI, 1.3-not estimable) in patients with PD-L1–positive tu-
mors, 1.3 months (95% CI, 1.1–6.3) in patients with
PD-L1–negative tumors, and 3.7months (95% CI, 1.4-not
estimable) in patients whose tumors were not evaluable
for PD-L1 expression. Median OS was 24.9 months
(95% CI, 6.2-not estimable), 4.9 months (95% CI, 3.8–
12.9), and not estimable (95% CI, 18.5-not estimable),
respectively (Additional file 3: Table S2 and Add-
itional file 5: Figure S3).
The confirmed ORR was 30.8% (95% CI, 14.3–51.8) in
patients who received prior ipilimumab therapy (n = 26),
compared with 12.0% (95% CI, 2.5–31.2) in patients who
did not (n = 25) (Table 2 and Additional file 2: Figure
S1). Median PFS of 6.3 months (95% CI, 1.4–9.5) in pa-
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Fig. 3 PFS (a) and OS (b) in patients with non-ocular and ocular melanoma
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with 2.8 months (95% CI, 1.4–4.1) in patients who did
not. Median OS was 16.2months (95% CI, 5.3 months-not
estimable) in patients who received prior ipilimumab
therapy compared with 17.2months (95% CI, 4.7 months-
not estimable) in patients who did not (Table 2).
ORRs for other subgroups can be found in Additional
file 2: Figure S1.
Safety
Overall, 50 patients (98.0%) had an AE (Additional file 6:
Table S3), 39 (76.5%) of whom had a treatment-related
AE (TRAE) of any grade (Table 3). The most com-
mon TRAEs (occurring in >10% of patients) were IRR
(n= 15 [29.4%]), fatigue (n= 9 [17.6%]), and chills (n=
6 [11.8%]). Grade 3 TRAEs occurred in 4 patients
(7.8%): nausea, gamma-glutamyltransferase increased,
hypokalemia, and lipase increased (n = 1 [2.0%] each). A
TRAE led to permanent discontinuation in 5 patients
(9.8%)—most commonly IRR (n = 3 [5.9%]), nausea (n = 1
[2.0%]), and sarcoidosis (n = 1 [2.0%]). Serious TRAEs oc-
curred in 3 patients (5.9%): IRR (resolved with concomi-
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Fig. 4 Best change in sum of target lesion diameters from baseline (a), and PFS (b) and OS (c) according to tumor PD-L1 expression status at 1%
cutoff in evaluable patients
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medication), and sarcoidosis (led to treatment discontinu-
ation). All serious AEs of any causality are shown in Add-
itional file 7: Table S4. No grade 4 TRAEs and no
treatment-related deaths were reported.
IRRs occurred at the first infusion in 8 patients
(15.7%), at the second infusion in 3 patients (5.9%), at
the third infusion in 1 patient (2.0%), and at the fourth
or later infusion in 3 patients (5.9%). IRRs led to treat-
ment discontinuation in 3 patients (5.9%). Five patients
(9.8%) experienced irAEs related to treatment, and all
were grade 1/2: hypothyroidism and pneumonitis (n = 2
[3.9%] each) and hyperthyroidism, sarcoidosis, and
vitiligo (n = 1 [2.0%] each) (Table 3). An irAE led to
treatment discontinuation in 1 patient (2.0%) due to
sarcoidosis (previously mentioned serious, treatment-re-
lated event).
Discussion
In this analysis of previously treated patients with
advanced melanoma, avelumab demonstrated durable
responses and promising survival outcomes. Of all en-
rolled patients, the confirmed ORR was 21.6 and 31.4%
in patients with non-ocular melanoma. These findings
are consistent with results from larger pivotal studies of
ICIs for second-line or later treatment of advanced
melanoma, which ranged from 21 to 37% [25–30]. After
a median follow-up of ≈2 years, the median DOR for
avelumab was not estimable in this cohort of patients,
consistent with findings after longer-term follow-up in
pivotal studies of other ICIs [26, 28, 30]. Median PFS
was 3.1 months and 3.9 months in patients with
non-ocular melanoma, which was also comparable to
that seen in these earlier pivotal studies [25–30], and
ongoing clinical benefit was observed in a subset of
patients—as evidenced by the plateau of the PFS curve.
Although the number of patients who had received prior
ipilimumab therapy in this analysis is small, the median
OS of 16.2 months is comparable to that reported in
studies of patients with advanced melanoma who
received pembrolizumab (KEYNOTE-002; 13.4 months
[2 mg/kg; n = 180] and 14.7 months [10 mg/kg; n = 181])
or nivolumab (CheckMate 037; 15.7months [n = 272])
following disease progression on ipilimumab [26, 28]. Add-
itionally, in a study of patients treated with pembrolizumab
who had received ≤1 prior therapy that did not include an
ICI (KEYNOTE-006), median OS had not been reached
after a median follow up of 22.9months [30].
Subgroup analyses suggested meaningful clinical activ-
ity in patients who had non-ocular primary tumors,
received prior ipilimumab therapy, or had PD-L1–posi-
tive tumors. In the JAVELIN Solid Tumor melanoma
cohort, no objective responses were observed in patients
with ocular melanoma, which is consistent with reported
ocular melanoma studies of other checkpoint inhibitors.
However, 7 of 16 patients (43.8%) with ocular melanoma
in this cohort had a best overall response of stable dis-
ease with avelumab, which may be explained by the min-
imal mutational load associated with ocular melanoma
[31]. Despite a lack of objective response in these pa-
tients, OS appeared comparable to that of patients with
non-ocular melanoma. Importantly, CheckMate 037,
KEYNOTE-002, and KEYNOTE-006 did not enroll pa-
tients with ocular melanoma. In patients who received
prior ipilimumab therapy, the confirmed ORR was
30.8%, which was consistent with that seen in
ipilimumab-refractory patients receiving nivolumab
(27%) or pembrolizumab (22% [2 mg/kg] and 28% [10
mg/kg]) [26, 28].
In patients evaluable for response according to PD-L1
expression, those with PD-L1–positive tumors had an
ORR of 42.1%—57.1% when confined to patients with
non-ocular melanoma—consistent with previous find-
ings from CheckMate 037 (43.6%) [25, 29, 30]. In this
study, patients with PD-L1–negative tumors did not
achieve an objective response, in contrast with the
observed modest efficacy in the much larger cohorts of
patients with PD-L1–negative tumors in pivotal studies
of ICIs [25–30]. However, a comparative study using
samples obtained from patients with non-small cell lung
Table 3 Incidence of treatment-related adverse events







Patients with ≥1 event 39 (76.5) 4 (7.8)
Infusion-related reaction 15 (29.4) 0
Fatigue 9 (17.6) 0
Chills 6 (11.8) 0
Diarrhea 5 (9.8) 0
Dysgeusia 4 (7.8) 0
Pyrexia 4 (7.8) 0
Aspartate aminotransferase increased 3 (5.9) 0
Dry mouth 3 (5.9) 0
Nausea 2 (3.9) 1 (2.0)
Gamma-glutamyltransferase increased 1 (2.0) 1 (2.0)
Hypokalemia 1 (2.0) 1 (2.0)
Lipase increased 1 (2.0) 1 (2.0)
All immune-related TRAEs
Patients with ≥1 event 5 (9.8) 0
Hypothyroidism 2 (3.9) 0
Pneumonitis 2 (3.9) 0
Hyperthyroidism 1 (2.0) 0
Sarcoidosis 1 (2.0) 0
Vitiligo 1 (2.0) 0
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cancer showed greater sensitivity of the PD-L1 immuno-
histochemistry assay used in this study (Dako 73–10)
compared with that used in the KEYNOTE 002 and 006
studies (Dako 22C3) [32], suggesting a possible discrep-
ancy in the ability to identify truly PD-L1–negative tu-
mors. Although prior post hoc analyses assessed the
association between response to nivolumab and PD-L1
expression across the full range of expression levels and
suggested that ORR increased with increasing PD-L1 ex-
pression, no PD-L1 expression threshold that may pre-
dict response to nivolumab was identified [26]. Future
research could endeavor to address whether additional
biomarkers, such as tumor mutational burden [33–35],
may identify subgroups of patients with either ocular or
PD-L1–negative tumors who respond to avelumab.
The safety profile was considered manageable and
tolerable, and generally consistent with that of other ICIs
and of studies of avelumab monotherapy in advanced
cancers [18–20]. In this study, grade 3 TRAEs occurred
in 7.8% of patients and no grade 4 events and no
treatment-related deaths were reported, compared with
grade 3/4 TRAEs occurring in ≈15% of patients in
studies of pembrolizumab and nivolumab, and few, but
notable, reported deaths [26, 28, 30]. In addition, no
grade 3/4 irAEs occurred compared with an incidence of
≈4% to 10% in these other studies [29, 31].
Conclusions
Avelumab showed durable responses, promising survival
outcomes, and an acceptable safety profile in patients
with previously treated metastatic melanoma, consistent
with other ICIs. Encouraging efficacy outcomes were
observed in patients with PD-L1–positive tumors and in
patients who had progressed on prior ipilimumab therapy.
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